After 3 months, the bone marrow cell differential was normocellular, showing 37.0% blasts, which were positive for myeloperoxidase staining and immunophenotypically positive for CD13, CD19, CD33, CD34, and HLA-DR, but negative for CD41. Following these observations, a diagnosis of transformation from t-MDS to t-AML was made. The disease progressed even though the patient had received induction therapy with low-dose cytarabine and aclarubicin. After 3 months, peripheral blood values were as follows: hemoglobin 65 g/L, platelets 17 × 10 9 /L, and WBCs 0.3 × 10 9 /L with 12% blasts. The bone marrow was infiltrated with two types of blasts: 40.4% large and 22.2% small blasts. The former were myeloblasts observed at the diagnosis of t-AML (Fig. 1a) . In contrast, small blasts showed cytoplasmic blebs, suggestive of megakaryoblasts (Fig. 1b) . These blasts were immunologically positive for CD7, CD13, CD33, CD34, CD41, and HLA-DR. The patient died of progressive disease 6 months after the initial diagnosis of t-MDS.
Double minute chromosomes (dmin) are small, acentric, extrachromosomal fragments that frequently mediate oncogene amplification, such as MYC at 8q24 or, less commonly, MLL at 11q23. They are rarely found in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), FAB classification subtypes M1 to M6.
A 66-year-old man was admitted because of pancytopenia. He had been diagnosed 2 years previously with recurrent rectal adenocarcinoma. After that diagnosis, this patient received irradiation followed by chemotherapy with capecitabine, oxaliplatin, and bevacizumab. Peripheral blood values were hemoglobin 103 g/L, platelets 39 × 10 9 /L, and white blood cells (WBCs) 1.1 × 10 9 /L with 51% segmented neutrophils, 10% monocytes, and 39% lymphocytes. The bone marrow was hypocellular with 0.2% blasts, 38.0% myeloid cells, 30.0% lymphocytes, and 25.4% erythroblasts. The patient was diagnosed as having therapy-related myeloid neoplasms, t-MDS.
MYC gene amplification frequently results in MYC protein overexpression [1] . Immunohistochemical staining for MYC protein was then performed on the bone marrow tissue at the final examination. About 60% of bone marrow cells showed low to high positivity for MYC protein expression (Fig. 1d) . Because megakaryoblasts proliferated during progression, double staining for nuclear MYC and surface CD41 was performed to examine the association between them. More than half of MYC-positive blasts were double positive for CD41 (Fig. 1e) .
In this report, we found that MYC gene amplification and MYC protein overexpression occurred in a patient with t-AML. The karyotype was complex and contained dmin that appeared during transformation from t-MDS to t-AML. At the diagnosis of t-AML, typical large myeloblasts proliferated and these cells were CD41 negative. However, during disease progression, the number of megakaryoblasts and myeloblasts increased and CD41 expression became positive. In addition, double staining immunohistochemistry could identify megakaryoblasts positive for nuclear MYC and surface CD41. Namely, these analyses confirmed that MYC-positive blasts were divided into CD41-negative myeloblasts and CD41-positive megakaryoblasts.
MYC amplification on dmin has been observed in <1% of AML. In several large-scale studies, the FAB classification of AML subtypes with dmin ranged from M1 to M6 of which about half of the cases were M2 [1] . To our knowledge, MYC amplification has, to date, not been reported in AML M7 or MDS that evolved to megakaryoblastic leukemia. MYC was previously shown to be required for megakaryocyte endomitosis and polyploidy formation, but its role in AML M7 has not been explored. The present findings, therefore, indicate that megakaryocytic lineage commitment with MYC amplification in MDS/AML harboring dmin can occur.
Huh et al. [1] reported that MYC protein expression was observed in all 18 cases of MDS/AML with dmin. High MYC expression is to be expected in cases with MYC amplification. However, interestingly, cases with dmin and MLL amplification also expressed MYC protein. As a result, MYC protein appears to be expressed in AML irrespective of the presence of MYC amplification. Further studies will be necessary to elucidate whether there is a specific association between MYC protein expression, MYC amplification, and other mechanisms of MYC activity regulation in AML.
